



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Paul J. Carter and Hongxing Zhou Docket No. 3492-US-PCT

Serial No.: 10/578,410

Art Unit: Not assigned

Filing Date: November 4, 2004

Examiner: Not assigned

For: ANTIBODIES THAT BIND INTERLEUKIN-4 RECEPTOR

CERTIFICATE OF MAILING

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Please find enclosed the following documents for the above-referenced patent application:

1. Postcard
2. Information Disclosure Statement
3. Form PTO-1449
4. 14 cited references

I hereby certify that this correspondence along with any referred to as being attached or enclosed, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Signed: _____

Jae Cho

Date: JANUARY 4, 2007



17a

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Paul J. Carter and Hongxing Zhou

Serial No.: 10/578,410

Group Art Unit No.: Not assigned

Filed: November 4, 2004

Examiner: Not assigned

For: ANTIBODIES THAT BIND INTERLEUKIN-4 RECEPTOR

Docket No.: 3492-US-PCT

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form, and provide(s) a copy of the listed references, B1-B8, and C1-C6, for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the reference(s) submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the reference(s).

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 09-0089 in the name of Immunex Corporation.

Please send all future correspondence to:

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, WA 98119-3105
(206) 265-7000

Respectfully submitted,

Nathan A. Machin
Attorney/Agent for Applicant(s)
Registration No.: 47,763
Phone: (206) 265-8779
Date: January 4, 2007

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. 3492-US-PCT Serial No. 10/578,410

Applicant Paul J. Carter and Hongxing Zhou

Filing Date 11/04/04 Group Not assigned

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	US 5,717,072	02/10/1998	Mosley et al.			
	A2	US 6,716,587	04/06/2004	Mosley et al.			
	A3						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B1	WO 01/92340	12/06/2001	PCT				
	B2	WO 96/33735	10/31/1996	PCT				
	B3	WO 96/34096	10/31/1996	PCT				
	B4	WO 94/21282	09/29/1994	PCT				
	B5	WO 91/09059	06/27/1991	PCT				
	B6	WO 00/18932	04/06/2000	PCT				
	B7	WO 90/05183	05/17/1990	PCT				
	B8	EP 0 604 693	07/06/1994	EP				

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	C1	Hultgren O., et al., "Staphylococcus aureus-induced septic arthritis and septic death is decreased in IL-4-deficient mice: role of IL-4 as promoter for bacterial growth." <i>J. Immunol</i> 1998:1605082-5087, May 1998.
	C2	Wills-Karp., et al., "Interleukin-13: Central Mediator of Allergic Asthma." <i>Science</i> 282:2258-2261, December 1998.
	C3	Holt LJ, et al., "Domain antibodies: proteins for therapy," <i>TRENDS in Biotech</i> , 21(11):484-490, November 2003.
	C4	Zurawski SM, et al., "The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor," <i>J. Biol Chem</i> 270(23):13869-13878, June 9, 1995.
	C5	Database EPOP: Accession No. AX356126, Feb 15, 2002.
	C6	Copy of related International Search Report for PCT/US01/17094.

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.